Amylin Pharmaceuticals Inc. (AMLN: Quote) reported data showing that the use of mealtime Symlin injection with basal insulin therapy for 24 weeks resulted in more patients achieving diabetes treatment goals of improved glucose control without weight gain or hypoglycemia in patients with type 2 diabetes.
This 24-week multi-center, randomized, open-label study, called INSTEAD or INitiating Symlin Therapy: Evaluating Alternatives in Diabetes, compared the safety and efficacy of the addition of mealtime Symlin or RAI to basal insulin therapy for 24 weeks in 112 patients with type 2 diabetes.
The study was designed to demonstrate improvement in pre-defined comprehensive diabetes treatment goals that included achieving a target A1C and experiencing no weight gain or episodes of severe hypoglycemia.
Click here to receive FREE breaking news email alerts for Amylin Pharmaceuticals Inc and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com